Blood pressure and heart failure: focused on treatment

Kyeong-Hyeon Chun1, Seok-Min Kang2

  • 1Division of Cardiology, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.

PubMed

Insights

Hypertension significantly contributes to heart failure (HF). Optimal blood pressure (BP) targets for HF patients are unclear, necessitating individualized treatment strategies rather than strict BP goals.

Area of Science:

  • Cardiology
  • Hypertension Research

Background:

  • Hypertension is a primary driver of heart failure (HF), a major global health issue.
  • The relationship between hypertension and HF, particularly HF with preserved ejection fraction, is significant.
  • Acute hypertensive HF presents challenges, with no specific vasodilator therapy proving universally beneficial.

Purpose of the Study:

  • To review the intricate connection between blood pressure (BP) and heart failure (HF).
  • To explore the pathophysiology linking BP and HF through existing clinical studies.
  • To address the clinical significance and optimal treatment targets for BP in HF patients.

Main Methods:

  • Literature review of clinical studies examining the relationship between BP and HF.
  • Analysis of pathophysiological mechanisms connecting hypertension and heart failure development.
  • Discussion of current treatment strategies and evidence gaps for BP management in HF.

Main Results:

  • Hypertension is a key factor in HF development, especially HF with preserved ejection fraction.
  • Optimal BP targets for HF patients lack definitive evidence, complicating treatment.
  • Current HF medications often lower BP, highlighting BP's importance as a hemodynamic marker.

Conclusions:

  • Individualized BP management within tolerable ranges is trending due to guideline gaps.
  • Further research is needed to establish concrete BP targets for HF treatment.
  • Understanding the BP-HF nexus is crucial for refining therapeutic strategies.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
665